Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

19 Jan, 2026

Authors: Anena D, Chappell E, Nazzinda R, Kiilu C, Chitsamatanga M, Arumugam T, Green A, Mutuluuza CK, Bwakura-Dangarembizi M, Siika A, Archary M, Jafta L, Namukwaya S, Seeley J, Akabwai G, Mugerwa H, Bevers L, Burger D, Walker S, Bamford A, South A, Apoto N, Bush M, Thomason MJ, Spittle B, Ford D, Kekitiinwa AR, Pett SL; LATA Trial Team.

Published in: Contemporary Clinical Trials